TNF gene polymorphism and its relation to intracerebral production of TNFα and TNFβ in AD

Neurology

Volumn 54, Issue 11, 2000, Pages 2077-2081

  Tarkowski, E ^a   Liljeroth, A M ^b   Nilsson, A ^b   Ricksten, A ^a   Davidsson, P ^a   Minthon, L ^b   Blennow, K ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c MEDICAL RESEARCH COUNCIL   (Sweden)

Author keywords

AD; Gene polymorphism; Tumor necrosis factor ; Tumor necrosis factor

Indexed keywords

LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FEMALE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0034643905     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.11.2077     Document Type: Article

References (36)

1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985;82: 4245-4249.
2. Banati RB, Beyreuther K. Alzheimer's disease. In: Kettenman H, Ransom BR, eds. Neuroglia. New York: Oxford University Press, 1995:1027-1043.
3. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neurol Sci 1989; 16:516-527.
4. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987;79:195-200.
5. St Pierre BA, Merill JE, Dopp JM. Effects of cytokines on the CNS cells: glia In: Ransohoff RM, Benveniste EN, eds. Cytokines and the CNS. Boca Raton, FL: CRC Press, 1996:151-168.
6. Bauer J, Ganter U, Strauss S, et al. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. 45th Forum in immunology. Res Immunol 1992;143:650-657.
7. Griffin WST, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989,86: 7611-7615.
8. Dickson DW, Lee SC, Mattiace LA, Yen S-HC, Brosnan C. Microglia and cytokines in neurological disease with special reference to AIDS and Alzheimer's disease. Glia 1993;7:75-83.
9. Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1-AL-6-mediated "acute phase response" in the brain? Immunol Today 1991;12:217-219.
10. Goldgaber D, Harris HW, Hla T, et al. Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989;86:7606-7610.
11. Licinio J, Wong M, Gold PW. Localization of interleukin-1 receptor antagonist mRNA in rat brain. Endocrinology 1991; 129:562-564.
12. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12-404-410.
13. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992;29:243-246.
14. Cheng B, Christakos S, Mattson MP. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 1994;12: 139-153.
15. Schwartz M, Solomon A, Lavie V, Ben BS, Belkin M, Cohen A. Tumor necrosis factor facilitates regeneration of injured central nervous system axons. Brain Res 1991;545:334-338.
16. 2+ accumulation. Proc Natl Acad Sci USA 1995;92:9328-9332.
17. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LBA, Duff GW. An allelic polymorphism within the human tumor necrosis factor α promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993;177:557-560.
18. McManus R, Wilson AG, Mansfield J, Weir DG, Duff GW, Kelleher D. TNF2, a polymorphism of the tumor necrosis-α gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. Eur J Immunol 1996; 26:2113-2118.
19. Pociot F, Briant L, Jongeneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993;23:224-231.
20. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor α promoter polymorphism effects transcription. Mol Immunol 1997;34:391-399.
21. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-3199.
22. Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an Ncol polymorphism in the first intron of the human TNF-β gene correlates with a variant amino acid in position 26 and a reduced level of TNF-β production. J Exp Med 1991;173:209-219.
23. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24: 381-384.
24. Folstein MF, Folstein SE, McHugh P. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
25. Wallin A, Blennow K, Scheltens PH. Research criteria for clinical diagnosis of "pure" Alzheimer's disease. Drugs Today 1994;30:265-273.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
27. (1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of the disease. Arch Neurol 1999;56:673-680.
28. (1-42) in CSF. In: Fischer A, Hanin I, Yoshida M eds. Progress in Alzheimer's and Parkinson's diseases. New York: Plenum Press, 1998:773-778.
29. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995;26:231-245.
30. Tarkowski E, Wallin A, Blennow K, Tarkowski A. Loca production of TNF-α, a potent neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999;19: 223-230.
31. 1-antichymotrypsin. Alzheimer Dis Assoc Disord 1998;3:215-227.
32. Tarkowski E, Rosengren L, Blomstrand C, et al. Intrathecal release of pro- and antiinflammatory cytokines in stroke. Clin Exp Immunol 1997;110:492-499.
33. Wilson AG, di Giovine FS, Duff GW. Genetics of tumor necrosis factor-α in autoimmune, infectious, and neoplastic diseases. J Inflamm 1995;45:1-12.
34. Andreasen N, Vanmechelen E, Van der Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow-up study. J Neurol Neurosurg Psychiatry 1998;64:298-305.
35. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945.
36. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of β-amyloid 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.